Simvastatin Improves Mortality of Heart Failure Patients

MAY 01, 2005
Susan Farley

A recent study showed that 40 mg per day of simvastatin significantly improved mortality in heart failure patients over a 1-year follow-up period, compared with not taking the drug at all. Patients taking the statin also were less likely to develop blockage of their arteries. Moreover, simvastatin users were less likely to require a second angioplasty and experienced a survival rate of 80%, compared with 57% among patients not taking the drug. According to Myung Ho Jeong, MD, of Chonnam National University Hospital in Korea, this study indicates that "patients suffering from heart attacks and consequent heart pump failure can be improved after routine statin therapy." He further concluded that simvastatin can be a good treatment in addition to aspirin to effectively aid heart failure patients who have undergone angioplasty for a heart attack.

Ms. Farley is a freelance medical writer based in Wakefield, RI.



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.